NEWRON PHARMACEUT. EO-20 (NP5) — Cash Flow Quality Index
NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow Quality Index of -1.11x as of December 2024. Operating cash flow of €-17.61 Million is below net income of €15.84 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore NP5 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
NEWRON PHARMACEUT. EO-20 Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for NEWRON PHARMACEUT. EO-20 across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see NEWRON PHARMACEUT. EO-20 (NP5) cash conversion ratio.
Annual Cash Flow Quality Index for NEWRON PHARMACEUT. EO-20 (2024–2024)
Year-by-year earnings quality comparison for NEWRON PHARMACEUT. EO-20.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -1.11x | €-17.61 Million | €15.84 Million | — |